Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and Granulocyte Colony-stimulating Factor (GCSF) in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome

Trial Profile

Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and Granulocyte Colony-stimulating Factor (GCSF) in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2013

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Ciclosporin; Filgrastim; Methylprednisolone
  • Indications Aplastic anaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jun 2012 Actual patient number is 53 according to ClinicalTrials.gov.
    • 21 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
    • 21 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top